Medical researcher

Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion to Expand Blood Cancer Portfolio

Eli Lilly and Company (NYSE:LLY) has agreed to acquire privately held biotechnology company Calytrix Bio in a cash transaction valued at up to $1.5 billion, expanding its development portfolio of treatments for rare blood cancers.

The agreement, announced by Calytrix on Monday, includes an initial cash payment and additional consideration linked to the achievement of specified clinical development and regulatory milestones.

The companies did not disclose the amount of the upfront payment or provide an expected closing date for the acquisition.

The transaction will add an investigational antibody therapy targeting rare blood disorders to Lilly’s existing oncology portfolio.

Acquisition Includes Upfront and Milestone-Based Payments

Under the terms of the agreement, Eli Lilly will acquire Calytrix Bio for total potential consideration of up to $1.5 billion.

The purchase price consists of an undisclosed upfront cash payment, together with additional payments contingent on the achievement of clinical trial and regulatory objectives.

The structure means the final amount paid will depend on the development progress and regulatory outcomes of Calytrix’s therapeutic programmes.

Calytrix did not specify the individual milestones, their associated payment amounts or the timetable for completing the transaction.

The acquisition represents a further investment by Lilly in pharmaceutical development outside its established diabetes and obesity treatment businesses.

Calytrix Develops Antibody Treatment for Rare Blood Disorders

Calytrix Bio’s principal development asset is an early-stage antibody therapy intended to treat essential thrombocythemia and myelofibrosis.

Both conditions are rare blood disorders associated with abnormal blood cell production in the bone marrow.

Essential thrombocythemia is characterised by excessive platelet production, while myelofibrosis involves changes to bone marrow tissue that interfere with normal blood cell formation.

The investigational therapy is being developed to address these conditions, although the announcement did not provide clinical efficacy results or specify a timetable for further studies.

The treatment remains at an early stage of development, and its eventual clinical and regulatory outcomes have not been established.

Lilly Continues Expansion Beyond Diabetes and Obesity Treatments

The proposed acquisition forms part of Eli Lilly’s broader efforts to expand its pharmaceutical portfolio beyond diabetes and weight-management medicines.

These businesses have been principal contributors to the company’s recent commercial growth, while Lilly has continued investing in other therapeutic areas.

The addition of Calytrix would increase the company’s exposure to treatments for rare haematological conditions.

Lilly already operates in the oncology market, including through Jaypirca, an FDA-approved medicine used to treat certain blood cancers.

The Calytrix acquisition would add an experimental antibody treatment to that existing portfolio, potentially broadening the company’s development activities in haematology.

Transaction Completion and Development Milestones Remain Outstanding

The companies have not announced a completion date for the acquisition or disclosed the initial cash consideration.

Additional payments under the agreement will depend on Calytrix’s achievement of the specified clinical and regulatory milestones.

The transaction’s maximum stated value of $1.5 billion therefore represents the total potential consideration rather than a confirmed upfront purchase price.

Following completion, the acquisition is expected to expand Eli Lilly’s pipeline of investigational therapies for rare blood disorders.

Further information about the transaction timetable and the development plans for Calytrix’s lead antibody programme has not yet been provided.

Eli Lilly stock price


Posted

in

by

Tags: